Modeling the dynamics of oral poliovirus vaccine cessation

Journal of Infectious Diseases

Volumn 210, Issue , 2014, Pages S475-S484

  Thompson, Kimberly M ^a,b   Tebbens, Radboud J Duintjer ^a  

^a Kid Risk Inc   (United States)

^b UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

disease outbreaks; dynamic modeling; oral poliovirus vaccine; polio eradication

Indexed keywords

ORAL POLIOMYELITIS VACCINE;

ARTICLE; DRUG USE; DYNAMICS; EPIDEMIC; HEALTH CARE POLICY; HUMAN; IMMUNITY; IMMUNIZATION; INFECTION RISK; MODEL; TREATMENT WITHDRAWAL; VIRUS TRANSMISSION; ADOLESCENT; ADULT; AGED; CHILD; DISEASE ERADICATION; FEMALE; INFANT; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; NEWBORN; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRESCHOOL CHILD; PROCEDURES; VACCINATION; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DISEASE ERADICATION; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINE, ORAL; VACCINATION; YOUNG ADULT;

EID: 84893080753     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jit845     Document Type: Article

References (24)

1. World Health Assembly. Global er adication of poliomyelitis by the year 2000 (resolution 41.28). Geneva, Switzerland: World Health Organization, 1988.
2. World Health Organization. Transmission of wild poliovirus type 2-Apparent global interruption. Wkly Epidemiol Rec 2001; 76:95-7.
3. World Health Organization. Global Polio Eradication Initiative: list of wild poliovirus by country. http://www.polioeradication.org/dataandmonitoring/poliothisweek/wildpolioviruslist.aspx. Accessed 29 September 2013.
4. World Health Assembly. Poliomyelitis: intensification of the global eradication initiative (resolution 65.5). Geneva, Switzerland: World Health Organization, 2012.
5. Duintjer Tebbens RJ, Pallansch MA, Kew OM, et al. Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication. Risk Anal 2006; 26:1471-505.
6. Duintjer Tebbens RJ, Pallansch MA, Kim JH, et al. Review: oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs). Risk Anal 20 13; 23:680-702.
7. Thompson KM, Duintjer Tebbens RJ, Pallansch MA, et al. The risks, costs, and benefits of possible future global policies for managing polioviruses. Am J Public Health 2008; 98:1322-30.
8. Thompson KM, Duintjer Tebbens RJ. The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation. Medscape J Med 2008; 10:190.
9. World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication (resolution 61.1). Geneva, Switzerland: World Health Organization, 2008.
10. Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SGF, Cochi SL. Modeling population immunity to support efforts to end the transmission of live polioviruses. Risk Anal 2013; 33:647-63.
11. Thompson KM, Duintjer Tebbens RJ, Pallansch MA. Evaluation of response scenarios to potential polio outbreaks using mathematical models. Risk Anal 2006; 26:1541-56.
12. Tho mpson KM, Duintjer Tebbens RJ. Current polio global eradication and control policy options: perspectives from modeling and prerequisites for OPV cessation. Expert Rev Vaccines 2012; 11:449-59.
13. Thomp son KM. Modeling poliovirus risks and the legacy of polio eradication. Risk Anal 2013; 33:505-15.
14. Duintjer Tebbens RJ, Thompson KM. Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation. J Infect Dis 2014; 210(suppl 1):S485-97.
15. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria. J Infect Dis 2014; 210 (suppl 1):S412-23.
16. Kalkowska DA, Duintjer Tebbens RJ, Thompson KM. Modeling strategies to incre ase population immunity and prevent poliovirus transmission in two high-risk areas in northern India. J Infect Dis 2014; 210 (suppl 1):S398-411.
17. Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM. Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccinerelated poliovir uses. Risk Anal 2013; 23:703-49.
18. Duintjer Tebbens RJ, Kalkowska DA, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM. The potential impact of expanding target age groups for polio i mmunization campaigns. BMC Infect Dis 2014; 14:45 doi:10.1186/1471-2334-14-45.
19. Diekmann O, Heesterbeek JA, Metz JA. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. J Math Biol 1990; 28: 365-82.
20. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Review and assessment of poliovirus immuni ty and transmission: synthesis of knowledge gaps and identification of research needs. Risk Anal 2013; 33:606-46.
21. Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, et al. Expert review on poliovirus immunity and transmission. Risk Anal 2013; 33:544-605.
22. World Health Organization. Global Polio Eradication Initiative: polio eradication and endgame strategic plan (2013- 2018). Geneva, Switzerland: World Health Organization, 2013.
23. Thompson KM, Duintjer Tebbens RJ. National policy choices related to inactivated poliovirus vaccine, innovation and the end game of polio global eradication. Expert Rev Vaccines 2014; 13:221-34.
24. Thompson KM, Pallansch MA, Duintjer Tebbens RJ,Wassilak SG, Kim J-H, Cochi SL. Pre-eradication vaccine policy options for poliovirus infection and disease control. Risk Anal 2013; 33:516-43.